Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

Clicks: 275
ID: 271584
2014
Vedolizumab was not more effective than placebo in inducing clinical remission at week 6 among patients with CD in whom previous treatment with TNF antagonists had failed. The therapeutic benefits of vedolizumab in these patients were detectable at week 10. ClinicalTrials.gov number: NCT01224171.
Reference Key
be2014gastroenterologyeffects Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sands BE;Feagan BG;Rutgeerts P;Colombel JF;Sandborn WJ;Sy R;D'Haens G;Ben-Horin S;Xu J;Rosario M;Fox I;Parikh A;Milch C;Hanauer S;;
Journal gastroenterology
Year 2014
DOI DOI not found
URL
https://www.pubmed.gov/24859203/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE Europe humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male aged middle aged young adult Remission Induction Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal Double-Blind Method Multicenter Study north america Brian G Feagan Humanized / therapeutic use* Gastrointestinal Agents / therapeutic use* time factors anti-inflammatory agents / therapeutic use* bruce e sands crohn disease / drug therapy* anti-inflammatory agents / adverse effects humanized / adverse effects tumor necrosis factor-alpha / metabolism israel treatment failure humanized / pharmacokinetics crohn disease / diagnosis crohn disease / immunology pmid:24859203 doi:10.1053/j.gastro.2014.05.008 video-audio media webcast stephen hanauer anti-inflammatory agents / pharmacokinetics drug substitution* gastrointestinal agents / adverse effects gastrointestinal agents / pharmacokinetics tumor necrosis factor-alpha / antagonists & inhibitors*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.